The in vivo and in vitro effects of an alkylating agent, mechlorethamine, on IL-6 production in mice and the role of macrophages

被引:10
作者
Bryniarski, K [1 ]
Ptak, M [1 ]
Ptak, W [1 ]
机构
[1] JAGIELLONIAN UNIV,COLL MED,DEPT IMMUNOL,PL-31121 KRAKOW,POLAND
来源
IMMUNOPHARMACOLOGY | 1996年 / 34卷 / 2-3期
关键词
mechlorethamine; cyclophosphamide; macrophages; IL-6;
D O I
10.1016/0162-3109(96)00130-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1. Since in vitro CY is inactive we have used in our experiments NM, a compound structurally and functionally related to phosphoramide mustard, the natural biologically active metabolite of CY. Thioglycollate late or oil-induced peritonal macrophages (Mf) of four different mouse strains treated with NM produce significantly more IL-6 than the non-treated cells. In contrast, under these conditions, the production of IL-1, TNF alpha and NO/NO2 radicals is not affected. The NM-induced elevated production of IL-6 by Mf could not be further increased by the treatment of cells with LPS, which may suggest that both agonists stimulate the same signalling pathway. The antineoplastic activity of the alkylating agents like CY or NM is usually attributed to the interstrand cross-linking of the DNA of the dividing cells. Our experiments can be tentatively interpreted as the induced overplus of IL-6 can also contribute to the stimulation of the cytotoxic NK-cells.
引用
收藏
页码:73 / 78
页数:6
相关论文
共 21 条
[1]   AUGMENTATION OF DELAYED-TYPE HYPERSENSITIVITY BY DOSES OF CYCLOPHOSPHAMIDE WHICH DO NOT AFFECT ANTIBODY-RESPONSES [J].
ASKENASE, PW ;
HAYDEN, BJ ;
GERSHON, RK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1975, 141 (03) :697-702
[2]  
DING AH, 1988, J IMMUNOL, V141, P2417
[3]   ENHANCING EFFECT OF LOW-DOSE CYCLOPHOSPHAMIDE TREATMENT ON INVITRO ANTIBODY-RESPONSE [J].
DUCLOS, H ;
GALANAUD, P ;
DEVINSKY, O ;
MAILLOT, MC ;
DORMONT, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1977, 7 (10) :679-684
[4]  
HEMMINKI K, 1985, CANCER RES, V45, P4237
[5]   BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6 [J].
HIRANO, T ;
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
IMMUNOLOGY TODAY, 1990, 11 (12) :443-449
[6]   CYTOKINE SIGNAL-TRANSDUCTION [J].
KISHIMOTO, T ;
TAGA, T ;
AKIRA, S .
CELL, 1994, 76 (02) :253-262
[7]   INTERLEUKIN-6 AND ITS RECEPTOR - A PARADIGM FOR CYTOKINES [J].
KISHIMOTO, T ;
AKIRA, S ;
TAGA, T .
SCIENCE, 1992, 258 (5082) :593-597
[8]  
LAGESTEHR J, 1978, NATURE, V241, P663
[9]  
LUGER TA, 1989, J IMMUNOL, V143, P1206
[10]   CYCLOPHOSPHAMIDE UNCOVERS 2 SEPARATE MACROPHAGE SUBPOPULATIONS WITH OPPOSITE IMMUNOGENIC POTENTIAL AND DIFFERENT PATTERNS OF MONOKINE PRODUCTION [J].
MARCINKIEWICZ, J ;
BRYNIARSKI, K ;
PTAK, W .
CYTOKINE, 1994, 6 (05) :472-477